Phathom Pharmaceuticals, Inc. (PHAT) AI Stock Analysis

Phathom Pharmaceuticals, Inc. is a biopharmaceutical firm headquartered in Florham Park, New Jersey, focused on developing and commercializing treatments for gastrointestinal diseases. The company holds exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker designed to inhibit stomach acid secretion. Its primary pipeline programs evaluate vonoprazan in Phase III clinical trials for erosive gastroesophageal reflux disease, as well as in combination with antibiotics to treat Helicobacter pylori bacterial infections. Founded in 2018 and employing 371 people, the company aims to address unmet clinical needs across common GI conditions.

Phathom's top line grew significantly from $682,000 in FY2023 to $55.3M in FY2024 and reached $175.1M in FY2025, representing a two-year revenue CAGR of 1502.4%. Gross margin strengthened from 75.5% in FY2023 to 85.6% in FY2024 and 87.1% in FY2025. Despite revenue expansion, heavy operating costs led to net losses of -$201.6M in FY2023, -$334.3M in FY2024, and -$221.2M in FY2025. In the trailing twelve months through June 30, 2026, revenue stood at $239.7M, supported by latest quarterly revenue growth of 88.0% year-over-year. Operating margin improved from -24532.6% in FY2023 to -5.3% over the trailing twelve months, while TTM net margin was -41.3%.

As of June 30, 2026, Phathom held $182.5M in cash and short-term investments alongside $167.1M in total debt, resulting in net cash of $15.4M. The company had total assets of $327.1M and a current ratio of 1.92. Due to cumulative losses, shareholders' equity was -$344.3M. Free cash flow for FY2025 was -$166.8M, reflecting cash burn from commercial and clinical operations against capital expenditures of $229,000. Additionally, the company's share count increased 121.8% over five years.

Phathom carries a market capitalization of $559.8M and an enterprise value of $550.1M. The stock trades at a forward P/E of 6.6x and a price-to-sales multiple of 2.3x, compared to the median of its US-listed Healthcare peers of 17.3x forward earnings and 4.1x sales. Over the trailing 12 months, PHAT shares fell 48.0%, trailing the S&P 500 benchmark gain of 16.8%. Over a 5-year span, the stock fell 78.7% while the S&P 500 rose 83.0%.

Wall Street coverage includes 8 Strong Buy, 2 Buy, and 2 Hold recommendations, with 0 Sell or Strong Sell ratings. The consensus mean price target is $20.09, representing an upside of 190.3% relative to the October 16, 2026 closing price of $6.92. Analysts project FY2026 revenue of $316.2M with an EPS of -$0.03. For FY2027, consensus estimates from 5 analysts anticipate revenue reaching $493.8M and EPS swinging positive to $1.05. The company beat EPS consensus in each of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Phathom Pharmaceuticals, Inc. (PHAT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PHAT income statement, PHAT balance sheet, PHAT key metrics, PHAT analyst forecast, PHAT chart. See the PHAT stock overview for the latest quote and news.